Boeing Working With Union, FAA to Review Employee Safety Reports
Bloomberg Businessweek
00:00
Weight Loss Drugs and Investment in Healthcare Sector
The chapter explores the impact of weight loss drugs from the GLP1 class on kidney disease, diabetes, and obesity, featuring Novo Nordus and Lilly's developments. It discusses the potential health benefits beyond weight loss, emphasizing the role of medication as part of a holistic approach to weight management. The narrative also delves into the challenges of maintaining weight loss post-medication and Eli Lilly's significant investment in expanding manufacturing capabilities for weight loss drugs.
Transcript
Play full episode
